UCB Biopharma SRL $UCB.BR
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS20
PHASE 3 / 2-317
RECRUITING9
READOUTS ≤12 MONTHS8
READOUT SLIPPED >6 MO60%
Delay Index: of 15 active trials registered more than a year ago, 9 have moved their primary completion (readout) date by more than 6 months since first registration (median +8.6 months). See all sponsors →
Open UCB Biopharma SRL on the live radar map → 📅 $UCB.BR readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Bimekizumab NCT06921850 |
P3 | Active, not recruiting | Hidradenitis Suppurativa | 43 | 2026-12-21 (-19 mo) |
| BE UNIQUE NCT06506916 |
P3 | Active, not recruiting | Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis | 89 | 2027-03-09 (+14 mo) |
| Staccato alprazolam NCT05077904 |
P3 | Recruiting | Stereotypical Prolonged Seizures | 350 | 2027-03-29 (+47 mo) |
| cosMOG NCT05063162 |
P3 | Active, not recruiting | Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) | 113 | 2027-05-06 (+21 mo) |
| ziMyG NCT06055959 |
P2/3 | Recruiting | Generalized Myasthenia Gravis | 8 | 2027-05-12 (+7 mo) |
| PossibILity NCT07277660 |
P2 | Active, not recruiting | Atopic Dermatitis | 165 | 2027-05-17 |
| rozanolixizumab NCT06540144 |
P3 | Active, not recruiting | Generalized Myasthenia Gravis | 13 | 2027-10-05 (-3 mo) |
| ziMyG+ NCT06435312 |
P3 | Enrolling by invitation | Generalized Myasthenia Gravis | 8 | 2027-10-26 |
| BeSeen NCT07219420 |
P3 | Recruiting | Palmoplantar Pustulosis | 320 | 2027-12-27 |
| Bimekizumab NCT06668181 |
P3 | Recruiting | Enthesitis-related Arthritis; Juvenile Psoriatic Arthritis | 40 | 2028-04-12 (+2 mo) |
| PHOENYCS FLY NCT06617325 |
P3 | Recruiting | Systemic Lupus Erythematosus | 450 | 2028-05-31 (+15 mo) |
| BE TOGETHER NCT06425549 |
P3 | Active, not recruiting | Moderate to Severe Plaque Psoriasis | 176 | 2028-08-21 |
| Staccato alprazolam NCT05076617 |
P3 | Enrolling by invitation | Stereotypical Prolonged Seizures | 300 | 2028-11-30 (+40 mo) |
| MyVision NCT07463521 |
P3 | Recruiting | Ocular Myasthenia Gravis | 120 | 2028-12-01 |
| ATMOS NCT07720375 |
P2 | Recruiting | Non-cystic Fibrosis Bronchiectasis | 300 | 2029-02-28 |
| SCALA NCT07725939 |
P2 | Recruiting | Chronic Obstructive Pulmonary Disease With Chronic Bronchitis | 402 | 2029-06-29 |
| Brivaracetam Film-coated tablet NCT06315322 |
P3 | Active, not recruiting | Childhood Absence Epilepsy; Juvenile Absence Epilepsy | 70 | 2029-11-16 (+9 mo) |
| Brivaracetam NCT04715646 |
P3 | Active, not recruiting | Epilepsy | 84 | 2030-07-08 (+63 mo) |
| Dapirolizumab pegol NCT04976322 |
P3 | Enrolling by invitation | Systemic Lupus Erythematosus | 760 | 2030-08-07 (+48 mo) |
| MyVisionXT NCT07465289 |
P3 | Recruiting | Ocular Myasthenia Gravis | 100 | 2031-03-17 |